4/12/2013

The FDA received Merck's new drug application for a tablet form of antifungal posaconazole, or Nozafil. The liquid formulation of the drug is already available to treat "severely immunocompromised" patients at high risk of developing Aspergillus and Candida infections.

Full Story:
PharmaTimes (U.K.)

Related Summaries